Literature DB >> 9894148

Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients.

Y S Hong1, J H Chang, O J Kwon, Y A Ham, J H Choi.   

Abstract

The levels of expressions and catalytic activities of cytochrome P450 (CYP1A1) and glutathione-S-transferase class mu (GSTM1) enzymes in lungs and their metabolic balance may be an important determinant host factor underlying lung cancer. Genetic differences in metabolism, MspI restriction sites, Ile-Val polymorphism of CYP1A1 gene, and the null genotype of GSTM1 have been reported to be associated with susceptibility to lung cancer. The present studies were undertaken to establish frequencies of the polymorphic genotypes of CYP1A1 and GSTM1 in Koreans, and to evaluate linkage disequilibrium of the genotypes associated with higher lung cancer risks among Koreans. GSTM1(-) genotype was found in 52% of control subjects, whereas it was found in 55% of lung cancer patients. The allelic variants in CYP1A1 were distributed differently in lung cancer patients and controls. The heterozygous genotype frequency of the MspI site in lung cancer patients (53%) was higher than in controls (49%). The frequency of Ile/Val genotype of CYP1A1 was low in lung cancer patients, which are mostly squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9894148     DOI: 10.1038/emm.1998.28

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  18 in total

1.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

2.  Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population.

Authors:  R C Sobti; S Sharma; A Joshi; S K Jindal; A Janmeja
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

3.  Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer.

Authors:  Chikako Kiyohara; Taro Shirakawa; Julian M Hopkin
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

4.  GSTM1 polymorphism and lung cancer risk among East Asian populations: a meta-analysis.

Authors:  Yan Zhao; Junjie Zeng; Yanxi Zhang; Su Lu; Erjiang Zhao; Ziming Huang; Weiquan Lu
Journal:  Tumour Biol       Date:  2014-04-01

5.  CYP1A1 exon7 polymorphism is associated with lung cancer risk among the female population and among smokers: a meta-analysis.

Authors:  Chun-hua Xu; Qin Wang; Qian Qian; Ping Zhan; Li-Ke Yu
Journal:  Tumour Biol       Date:  2013-07-07

6.  Glutathione S-transferase M1 and T1 null genotype frequency distribution among four tribal populations of western India.

Authors:  Prem Chandra Suthar; Pulakes Purkait; Kiran Uttaravalli; B N Sarkar; Rakshit Ameta; Mithun Sikdar
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

7.  Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis.

Authors:  Wen Li; Li-Qiang Song; Jian Tan
Journal:  Tumour Biol       Date:  2014-06-18

8.  CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis.

Authors:  Ya-Nan Ji; Qin Wang; Li-Jun Suo
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

Review 9.  CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review.

Authors:  Ping Zhan; Qin Wang; Qian Qian; Shu-Zhen Wei; Li-Ke Yu
Journal:  J Exp Clin Cancer Res       Date:  2011-10-20

10.  CYP1A1 and GSTM1/T1 genetic variation in predicting risk for cerebral infarction.

Authors:  Kyung-Suk Moon; Hye-Jung Lee; Seung-Heon Hong; Hyung-Min Kim; Jae-Young Um
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.